Kymeta Demonstrates LEO and GEO SATCOM Interoperability During Military Battle Lab Exercise
22.7.2021 16:00:00 EEST | Business Wire | Press release
Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today seamless interoperability between the Kymeta™ u8 terminal, Kepler Communications low earth orbit (LEO) satellites, and geostationary (GEO) SATCOM terminals at an annual military battle lab exercise focused on the integration of operations, intelligence, and technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005039/en/
Kymeta demonstrates LEO and GEO interoperability with the u8 at technical demonstration. (Photo: Business Wire)
The u8 is the first and only terminal available today to demonstrate the automatic handover between a GEO SATCOM terminal and Kepler LEO constellation with high throughput for communications on the move (COTM) and on the pause (COTP). Today’s warfighters require access to command and control (C2) networks providing message traffic, email, VoIP, and VTCs as well as higher throughput networks for sending and receiving large amounts of data. The demonstration proved that access to C2 networks and high throughput communications is possible with a single integrated terminal, the u8.
“While today’s mobile forces operating in remote environments may have communication access through a traditional very small aperture terminal (VSAT) or legacy COTM terminals, they do not have access to the high-throughput LEO constellations,” said Rob Weitendorf, Vice President, Business Development, Kymeta. “The u8 provides the needed capacity and seamless connectivity between LEO and GEO satellites. We could not be more thrilled with the excitement our demo received from the Special Forces community at the event.”
Three stationary ground stations with GEO and LEO capabilities located in Inuvik, Canada, Redmond, WA, and Tuscon, AZ were combined with one mobile terminal at the demonstration Virginia Beach, VA. Each station had access to six Kepler LEO satellites and two GEO satellites. The change from GEO to LEO and linear to circular polarization was automated and accomplished via software only. Kymeta and Kepler’s experimentation was focused on providing high data rate point-to-point communications where data was transmitted from ground station to ground station without connection to the cloud, followed by GEO SATCOM for day-to-day operations.
Results exceeded expectations and demonstrated a significant increase in performance with lower latency, enhanced look angles, and speeds that are approaching 10X faster than earlier products with higher throughput and total data passed. Testing results included download speeds of 240 Mbps and upload speeds of 193 Mbps achieved with over 2 GB of data transferred during a single LEO pass. This capability has utility in polar regions where access to high-throughput communications is unavailable and mechanically-steered antennas struggle in low temperatures.
The demonstration further validates Kymeta’s ability to provide a LEO upgrade path for its u8 terminals and seamlessly leverage hybrid connectivity across multiple satellite constellations and ground LTE. Kymeta is the only flat-panel antenna (FPA) with electronic beam steering and no moving parts built for mobility and designed for the needs of military, public safety, and commercial customers.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005039/en/
Contact information
Business Inquiries for Kymeta:
Brenda Kuhns
Director of Marketing
Kymeta Corporation
bhuhns@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Director of PR & Content
The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom